Clinical Trial Update: CPC-201 Alzheimer's Disease Type Dementia: PET Study [Phase 2]

View source ↗

Summary

The Phase 2 Alzheimer's disease PET study CPC-201 has been withdrawn. Sponsor is Chase Pharmaceuticals Corporation, an affiliate of Allergan plc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CPC-201

Snippet

Sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | Conditions: Alzheimer's Disease | Phase 2 | Status: WITHDRAWN